| 货号 | HV219016 |
|---|
| 品牌 | abinScience |
|---|
| 种属反应性 | Human |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 同种型 | IgG1-kappa |
|---|
| 克隆号 | PY159 |
|---|
| 生物活性 | PY159 induceS signaling, upregulate monocyte activation markers, and stimulate proinflammatory cytokine production in human whole blood and dissociated primary tumor cells in vitro [3]. |
|---|
| 表达系统 | Mammalian cells |
|---|
| 靶标 | TREM1, Triggering receptor expressed on monocytes 1, Triggering receptor expressed on myeloid cells 1, TREM-1, CD354 |
|---|
| 内毒素水平 | < 10 EU/mg |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| Accession号 | Q9NP99 |
|---|
| 状态 | Liquid |
|---|
| 保存溶液 |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
|---|
| 别名 | PY159 |
|---|
| 背景 | Triggering receptor expressed on myeloid cells 1 (CD354/TREM1) is a ~26 kDa protein. Cell surface receptor that plays important roles in innate and adaptive immunity by amplifying inflammatory responses. Upon activation by various ligands such as PGLYRP1, HMGB1 or HSP70, multimerizes and forms a complex with transmembrane adapter TYROBP/DAP12. In turn, initiates a SYK-mediated cascade of tyrosine phosphorylation, activating multiple downstream mediators such as BTK, MAPK1, MAPK3 or phospholipase C-gamma. This cascade promotes the neutrophil- and macrophage-mediated release of pro-inflammatory cytokines and/or chemokines, as well as their migration and thereby amplifies inflammatory responses that are triggered by bacterial and fungal infections. By also promoting the amplification of inflammatory signals that are initially triggered by Toll-like receptor (TLR) and NOD-like receptor engagement, plays a major role in the pathophysiology of acute and chronic inflammatory diseases of different etiologies including septic shock and atherosclerosis. 1. Bouchon, A. et al. (2000) Journal of immunology (Baltimore, Md. : 1950) 164, 4991-5. PMID: 107998492. Arts, RJ. et al. (2011) European cytokine network 22, 11-4. PMID: 213931023. El Mezayen, R. et al. (2007) Immunology letters 111, 36-44. PMID: 175686914. Read, CB. et al. (2015) Journal of immunology (Baltimore, Md. : 1950) 194, 1417-21. PMID: 255957745. Carrasco, K. et al. (2019) Cellular & molecular immunology 16, 460-472. PMID: 295681196. Radaev, S. et al. (2003) Structure (London, England : 1993) 11, 1527-35. PMID: 146564378. Fortin, CF. et al. (2007) International immunology 19, 41-50. PMID: 17098818 |
|---|
| 文献 | 1. Oladapo Yeku, et al. Evaluation of myeloid targeting agents, PY159 and PY314, in two dose expansion phase Ib trials in platinum-resistant ovarian cancer. December 2023. Immuno-Oncology Technology. [HV219016]
2. Yeku OO, et al. Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. J Immunother Cancer. 2025;13(3):e010959. Published 2025 Mar 13. [HV219016]
3. Nadine Jahchan, et al. Tuning the tumor microenvironment by reprogramming TREM1+ myeloid cells to unleash anti-tumor immunity in solid tumors. Journal for ImmunoTherapy of Cancer. November 2021. 9(Suppl 3):A900-A900 [HV219016]
4. Ira Seth Winer, et al. A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1). J Clin Oncol 41, 2523-2523(2023). View More [HV219016] |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
| Isotype Control | Human IgG1 (LALAPG) Recombinant Isotype Control Antibody (HyHEL-10) (HP688307) |
|---|
